iVascular Expands its Facilities in Catalonia with an Investment of 15 Million

iVascular reinforces its facilities in Catalonia. The Spanish company that develops medical devices will invest €15 million in the expansion of its center in Sant Vicenç del Horts (Barcelona).

The investment aims to triple the plant’s current surface area, allocating more than 1,700 square meters to ISO 7 rooms and more than 400 square meters to ISO 8 rooms, in order to increase its current production capacity sixfold and continue to grow exponentially. The expansion of iVascular’s facilities responds to the need to increase the company’s production capacity in order to maintain this growth rate.

Thanks to this investment project, the company will also increase its human team, currently made up of more than 350 people, according to the medical device company in a press release.

Read more about iVascular and discover the world’s most interesting business headlines with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

iVascular will allocate €40 million to R&D&I over the next five years

In addition to the factory expansion project, iVascular estimates that over the next five years it will allocate €40 million to investments in research, development, and innovation (R&D&I) and in its commercial expansion on a global scale.

The company emphasizes its leading role in the field of cardiovascular pathology, which is why it invests 15% of its turnover in R&D&I every year. iVascular’s main objective is to provide technological solutions to medical professionals so that they can treat their patients in the most efficient way.

The company designs, manufactures, and markets more than 1,500 advanced medical devices. Its stents, balloons, and catheters are used in hospitals around the world and they estimate that by 2025 they will have improved the quality of life of more than two million people.

iVascular transforms metal tubes into stents, plastic pellets into catheters, and designs its own polymers to improve the characteristics of its medical devices. With 90% exports, the company’s products are approved in more than 80 countries around the world.

The group expects to boost its turnover to more than €50 million this year. This figure would represent an increase of more than 30% in sales in 2021. Last year, iVascular had a turnover of €38.5 million. The company was founded in 2010 and has focused on vascular pathologies in three application areas: interventional cardiology, endovascular interventionism, and neuroradiology.

__

(Featured image by smartschwaz via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.